Plural Six-membered Hetero Rings Consisting Of One Nitrogen And Five Carbon Atoms Patents (Class 514/332)
-
Publication number: 20110105556Abstract: Provided are tris-quaternary ammonium compounds which are modulators of nicotinic acetylocholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and/or treatment of central nervous system disorders, substance use and/or abuse and or gastrointestinal tract disorders.Type: ApplicationFiled: December 22, 2006Publication date: May 5, 2011Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONInventors: Peter A. Crooks, Linda P. Dwoskin, Roger Papke, Guangrong Zheng, Sangeetha Sumithran
-
Patent number: 7935825Abstract: According to the invention there is provided a compound the formula I; wherein A, X, B, R1, R2, R3 and R4 are as defined in the specification.Type: GrantFiled: May 4, 2007Date of Patent: May 3, 2011Assignee: Allergan, Inc.Inventors: Robert M. Burk, Sophie Beauchemin
-
Publication number: 20110098275Abstract: The present invention encompasses compounds of general formula (1) wherein R1 to R4, m and n are defined as in the specification, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.Type: ApplicationFiled: April 20, 2010Publication date: April 28, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Tobias Wunberg, Siegfried Schneider, Lars Van Der Veen
-
Patent number: 7932270Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.Type: GrantFiled: July 31, 2007Date of Patent: April 26, 2011Assignee: Cytokinetics, Inc.Inventors: Pu-Ping Lu, Xiangping Qian, Jeffrey T. Finer, Chihyuan (Grace) Chuang, Bradley P. Morgan, David J. Morgans, Jr.
-
Publication number: 20110092461Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.Type: ApplicationFiled: December 6, 2010Publication date: April 21, 2011Inventors: Janet L. GUNZNER, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina
-
Publication number: 20110091551Abstract: A wound covering includes a) a transparent film and b) applied to the film, a transparent hydrogel which includes octenidine dihydrochloride. The wound covering is suitable in particular for use in the antisepsis of catheter insertion points. The active ingredient octenidine dihydrochloride is released from the hydrogel quickly, but in a long-lasting manner. A wound covering set and a hydrogel including octenidine dihydrochloride for use for the antisepsis of catheter insertion points are also described.Type: ApplicationFiled: October 13, 2010Publication date: April 21, 2011Applicant: LAIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE CLAUDEInventors: Boris BAUR, Andreas DETTMANN, Sabine BEHRENDS
-
Publication number: 20110092537Abstract: The present invention relates to 2,6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compounds of the present invention can also be used in the treatment of ocular diseases associated with pathological abnormalities/changes in the tissues of the visual system.Type: ApplicationFiled: October 15, 2010Publication date: April 21, 2011Applicant: AC Immune S.A.Inventors: Heiko Kroth, Wolfgang Froestl, Andrea Pfeifer, Andreas Muhs
-
Publication number: 20110092543Abstract: The invention relates to an antimicrobially effective composition which comprises a) 0.001 to 1% by weight of bispyridiniumalkane, b) humectant and c) water. The composition has an osmolality of from 230 to 350 mOsmol/kg and is free from surfactant. It is used as wound and mucosa antiseptic.Type: ApplicationFiled: October 14, 2010Publication date: April 21, 2011Applicant: L'Air Liquide Societe Anonyme Pour L'Etude Et L'Exploitation Des Procedes Georges ClaudeInventors: Boris Baur, Sabine Behrends, Jörg Siebert, Andreas Dettmann, Mona Golombiewski
-
Patent number: 7919511Abstract: Chemical entities that modulate smooth muscle myosin and/or non-muscle myosin, and chemical entities, pharmaceutical compositions and methods of treatment of diseases and conditions associated with smooth muscle myosin and/or non-muscle myosin are described.Type: GrantFiled: July 31, 2007Date of Patent: April 5, 2011Assignee: Cytokinetics, Inc.Inventors: Pu-Ping Lu, Xiangping Qian, Jeffrey T. Finer, Chihyuan (Grace) Chuang, Bradley P. Morgan, David J. Morgans, Jr.
-
Publication number: 20110076242Abstract: A description is given according to the invention of a composition on an aqueous basis which comprises a) 0.001 to 10% by weight bispyridinium alkane, b) 0.1 to 30% by weight nonionic surfactant, c) 0 to 40% by weight aromatic alcohol and d) 0.01 to 10% by weight polyol selected from alkanediols and alkanetriols. The compositions, as mouthwash solutions, are more active than current commercial products and are distinguished by a pleasant taste and low tendency to foaming.Type: ApplicationFiled: October 23, 2007Publication date: March 31, 2011Applicant: Air Liquide SanteInventors: Sabine Behrends, Boris Baur, Thomas Spuida, Andreas Dettmann, Joachim Thiede
-
Publication number: 20110077160Abstract: Compounds having the following generic formula are disclosed.Type: ApplicationFiled: December 7, 2010Publication date: March 31, 2011Inventors: Nneka T. Breaux, Michael R. Loso, Timothy C. Johnson, Jonathan M. Babcock, Benjamin M. Nugent, Timothy P. Martin, Annette V. Brown, Ronald Ross, JR., William C. Lo, Matthias S. Ober
-
Publication number: 20110077237Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.Type: ApplicationFiled: April 1, 2010Publication date: March 31, 2011Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Juan-Miguel Jimenez, Guy W. Bemis, Francois Maltais, Tiansheng Wang, Ronald Knegtel, Chris Davis, Damien Fraysse, Dean Boyall, Luca Settimo, Stephen Young, Michael Mortimore
-
Publication number: 20110071165Abstract: Aza- and polyazanthranyl amides and their use as medicaments in the treatment of diseases caused by persistent angiogenesis are described, as well as the intermediates used in the preparation of the aza- and polyazanthranyl amides.Type: ApplicationFiled: November 24, 2010Publication date: March 24, 2011Applicant: NOVARTIS AGInventors: Dieter SEIDELMANN, Martin KRÜGER, Orlin PETROV, Andreas HUTH, Karl-Heinz THIERAUCH, Andreas MENRAD, Martin HABEREY
-
Publication number: 20110065683Abstract: The present invention relates to 1-alkyl-3-aniline-5-aryl-pyrazole derivatives and pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I). The invention particularly relates to positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.Type: ApplicationFiled: May 8, 2009Publication date: March 17, 2011Inventors: Johannes Wilhelmus John F. Thuring, Gregor James MacDonald, Wei Zhuang
-
Publication number: 20110065577Abstract: The present invention relates to pyridin-4-ylmethyl sulfonamides of formula I wherein Ra, n, R, A and Het are as defined in the claims, to the N-oxides, and salts thereof and their use for combating harmful fungi, and also to compositions and seed comprising at least one such compound. The invention also relates to a process and intermediates for preparing these compounds.Type: ApplicationFiled: May 15, 2009Publication date: March 17, 2011Applicant: BASF SEInventors: Wassilios Grammenos, Alice Glaettli, Jan Klaas Lohmann, Michael Puhl, Bernd Mueller, Marianna Vrettou
-
Publication number: 20110053975Abstract: The present invention relates to a compound of one of the formulas I to XXI; a pharmaceutical composition comprising at least one such compound; and the use of at least one such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.Type: ApplicationFiled: January 12, 2009Publication date: March 3, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS, INSTITUT CURIE, UNIVERSITE MONTPELLIER 2 SCIENCES ET TECHNIQUESInventors: Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux
-
Publication number: 20110039841Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPAR? subtype.Type: ApplicationFiled: May 3, 2005Publication date: February 17, 2011Applicants: Novo Nordisk A/SInventors: Zdenék Polivka, Karel Sindelar, Per Sauerberg, Ingrid Pettersson
-
Publication number: 20110039892Abstract: The present invention aims to provide a compound having a superior selective ?1D adrenergic receptor antagonistic action and useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like. The present invention provides a compound represented by the formula (I) wherein each symbol is as defined in the specification, or a salt thereof.Type: ApplicationFiled: April 21, 2009Publication date: February 17, 2011Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Masato Yoshida, Yasuhisa Kohara, Nobuki Sakauchi, Ayumu Sato
-
Patent number: 7888364Abstract: The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.Type: GrantFiled: September 2, 2005Date of Patent: February 15, 2011Assignee: Curis, Inc.Inventors: Janet L. Gunzner, Daniel Sutherlin, Mark S. Stanley, Liang Bao, Georgette M. Castanedo, Rebecca L. Lalonde, Shumei Wang, Mark E. Reynolds, Scott J. Savage, Kimberly Malesky, Michael S. Dina
-
Patent number: 7888374Abstract: The present invention relates to compounds that are inhibitors of c-jun N-terminal kinase 1, 2, or 3 (JNK1, JNK2, or JNK3), compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the activation of JNK1, JNK2 and JNK3.Type: GrantFiled: January 23, 2006Date of Patent: February 15, 2011Assignee: Abbott LaboratoriesInventors: Gang Liu, Hing L. Sham, Bruce G. Szczepankiewicz, Zhili Xin, Hongyu Zhao, Michael D. Serby, Bo Liu, Mei Liu
-
Publication number: 20110034378Abstract: The present invention relates to a combination, such as a combined preparation or pharmaceutical composition comprising: (a) compound of formula (I), and/or (II) or a pharmaceutically acceptable salt thereof; (b) at least one therapeutic agent selected from the group consisting of: an antihypertensive agent; an antidiabetics agent; a hypolipidemic agent; an antiplatelet agent; an antiobesity agent; an antithrombotic agent; an agent for diabetic vascular complications; and an agent for treatment of heart failure; or a pharmaceutically acceptable salts thereof, optionally in presence of a pharmaceutically acceptable carrier for separate, simultaneous or sequential use. The present invention also relates to a use of such combination for the treatment of mammal including human being. R1, R2, R3, R1, R2, R3, R4, R5, X, Y, A and B and m are as defined in the specification.Type: ApplicationFiled: January 21, 2009Publication date: February 10, 2011Inventors: Chaitanya Dutt, Deepa Joshi, Ram Gupta, Kumarprafull Chandra
-
Publication number: 20110028492Abstract: The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.Type: ApplicationFiled: July 26, 2010Publication date: February 3, 2011Inventors: Paul A. Barsanti, Cheng Hu, Jeff Jin, Robert Keyes, Robert Kucejko, Xiaodong Lin, Yue Pan, Keith B. Pfister, Martin Sendzik, James Sutton, Lifeng Wan
-
Patent number: 7879839Abstract: The present invention relates to compounds having the structure useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.Type: GrantFiled: July 27, 2005Date of Patent: February 1, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Christopher J. Dinsmore, Jeffrey M. Bergman, Douglas C. Beshore, B. Wesley Trotter, Kausik K. Nanda, Richard Isaacs, Linda S. Payne, Lou Anne Neilson, Zhicai Wu, Mark T. Bilodeau, Peter J. Manley, Adrienne E. Balitza
-
Patent number: 7875633Abstract: A compound represented by the formula (I) is contained as an active ingredient: wherein R1 and R2 independently represent a hydrogen atom, a lower alkyl group or the like, or R1 together with a nitrogen atom to which L, Z2 and R1 are attached may form an aliphatic nitrogenated heterocyclic group and R1 and R2 together with a nitrogen atom to which they are attached may form an aliphatic nitrogenated heterocyclic group; X represents a methine group or a nitrogen atom; Y represents —CH2—O—, —CH?CH— or the like; Z1 represents a single bond, a C1-4 alkylene group or the like; Z2 represents a single bond or a C1-4 alkylene group; L represents a methylene group, a C3-8 cycloalkylene group or the like; and Ar represents an aromatic carbocyclic group or the like. The compound is useful as a pharmaceutical for a central nerves system disease, a cardiovascular disease or a metabolic disease.Type: GrantFiled: August 23, 2006Date of Patent: January 25, 2011Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Akira Naya, Toshihiro Sakamoto, Yuji Haga, Norikazu Otake
-
Publication number: 20110015184Abstract: The invention relates to compounds of structural formula (Ia): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein X1, X2, X3, X4, X6, X10, R1, Y, Z, L, and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.Type: ApplicationFiled: September 28, 2010Publication date: January 20, 2011Applicant: Synta Pharmaceuticals Corp.Inventors: Gary Bohnert, Shoujun Chen, Yu Xie
-
Patent number: 7872029Abstract: The present invention relates to chalcone and chalcone derivatives and analogs which are useful as angiogenesis inhibitors. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good activity as angiogenesis inhibitors. The present invention also relates to the use of chalcone and its analogs as antitumor/anticancer agents and to treat a number of conditions or disease states in which angiogenesis is a factor, including angiogenic skin diseases such as psoriasis, acne, rosacea, warts, eczema, hemangiomas, lymphangiogenesis, among numerous others, as well as chronic inflammatory disease such as arthritis.Type: GrantFiled: August 22, 2008Date of Patent: January 18, 2011Inventors: J. Phillip Bowen, Thomas Philip Robinson, Tedman Ehlers, David Goldsmith, Jack Arbiser
-
Publication number: 20110009447Abstract: Substituted benzoic acid amides of formula (I) and their use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis as well as their intermediate products for the production of benzoic acid amides are described.Type: ApplicationFiled: April 24, 2001Publication date: January 13, 2011Inventors: Andreas Huth, Dieter Seidelmann, Karl-Heinz Thierauch
-
Publication number: 20110009421Abstract: An object of the present invention is to provide an agent for preventing or treating schizophrenia or the like, wherein the compound of the present invention has GPRS2 agonist activity.Type: ApplicationFiled: February 27, 2009Publication date: January 13, 2011Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Masaki Setoh, Toshitake Kobayashi, Toshio Tanaka, Atsuo Baba
-
Publication number: 20110003857Abstract: An aqueous-based composition which includes a) at least one bispyridinium alkane (for example octenidine) and b) at least one stabilizer selected from antioxidants, complexing agents, reducing agents, UV filters and photoprotective agents, in particular ?-tocopherol, and BHT. The composition can also include c) one or more auxiliaries selected from, for example, nonionic surfactants, ethers, solvents and polymers, in particular fatty alcohol alkoxylates and alkoxylated fatty acid monoglycerides. The presence of the stabilizer reduces or prevents the appearance of decomposition products of bispyridinium alkanes and, in the case of the presence of auxiliaries, of decomposition products of the auxiliaries, such as ethers and peroxides.Type: ApplicationFiled: February 18, 2009Publication date: January 6, 2011Applicant: AIR LIQUIDE SANTE (INTERNATIONAL)Inventors: Wolfgang Beilfuss, Andreas Dettmann, Sabine Behrends, Mona Golombiewski, Thomas Spuida, Elke Kassens
-
Publication number: 20110003783Abstract: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent.Type: ApplicationFiled: April 8, 2010Publication date: January 6, 2011Inventor: David J. Bova
-
Patent number: 7863293Abstract: The present invention relates to compounds that bind to chemokine receptors, and having the formula wherein each A, X, Y, R1, R2 and R3 are substituents. The present invention also relates to methods of using such compounds, such as in treating HIV infection and inflammatory conditions such as rheumatoid arthritis. Furthermore, the present invention relates to methods to elevate progenitor and stem cell counts, as well as methods to elevate white blood cell counts, using such compounds.Type: GrantFiled: November 6, 2007Date of Patent: January 4, 2011Assignee: Genzyme CorporationInventors: Gary J. Bridger, Ernest J. McEachern, Renato Skerlj, Dominique Schols, Ian Baird, Al Kaller, Curtis Harwig, Yongbao Zhu, Gang Chen, Krystyna Skupinska
-
Patent number: 7858628Abstract: The present invention provides a group of compounds found to increase the number of neurons derived from stem cells for use as a therapeutic agent in neurological conditions or diseases. In one embodiment of the present invention, the compounds are used to detect the mechanism by which the number of neurons is increased.Type: GrantFiled: July 9, 2009Date of Patent: December 28, 2010Assignee: Neuralstem, Inc.Inventors: Judith Kelleher-Andersson, Karl K. Johe
-
Publication number: 20100324092Abstract: The present invention relates to a novel class of pyridyl and pyrimidinyl derivatives. The pyridyl and pyrimidinyl compounds can be used to treat cancer. The pyridyl and pyrimidinyl compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: ApplicationFiled: June 24, 2008Publication date: December 23, 2010Inventors: Richard W. Heidebrecht, JR., Thomas A. Miller, Matthew G. Stanton, David J. Witter
-
Publication number: 20100324093Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: August 26, 2010Publication date: December 23, 2010Applicant: Millennium Pharmaceuticals, Inc.Inventors: Paul Fleming, Geraldine C.B. Harriman, Zhan Shi, Shaowu Chen
-
Publication number: 20100324046Abstract: The present invention relates to a novel class of 4-carboxybenzylamino derivatives. The 4-carboxybenzylamino compounds can be used to treat cancer. The 4-carboxybenzylamino compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases.Type: ApplicationFiled: June 24, 2008Publication date: December 23, 2010Inventors: Paul Harrington, Richard W. Heidebrecht, JR., Solomon Kattar, Thomas A. Miller, Karin M. Otte, Phieng Siliphaivanh, Paul Tempest, Kevin J. Wilson, David J. Witter
-
Publication number: 20100317643Abstract: The invention provides compounds of Formula I, stereoisomers or pharmaceutically acceptable salts thereof, wherein A, B, D, R1, R2, R4 and R5 are defined herein, a pharmaceutical composition that includes a compound of Formula I and methods of use thereofType: ApplicationFiled: June 10, 2010Publication date: December 16, 2010Applicant: GENENTECH, INC.Inventors: SIMON CHARLES GOODACRE, YINGJIE LAI, JUN LIANG, STEVEN R. MAGNUSON, KIRK D. ROBARGE, MARK S. STANLEY, VICKIE HSIAO-WEI TSUI, KAREN WILLIAMS, BIRONG ZHANG, AIHE ZHOU
-
Patent number: 7851489Abstract: The invention is directed to pyridinone compounds useful for modulating Met kinase, having the following structure: and is further directed to pharmaceutical compositions comprising the compound; and methods for treating proliferative diseases, such as cancer by the administration of this compound.Type: GrantFiled: November 8, 2007Date of Patent: December 14, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Robert M. Borzilleri, Gretchen M. Schroeder, Zhen-Wei Cai
-
Publication number: 20100310487Abstract: An active ingredient combination which comprises a) glycerol monoalkyl ether, b) bispyridinium alkane, c) polyol and d) antioxidant. The combination is advantageously used for producing a preparation for the treatment of undesired body odour, for example for producing a cosmetic deodorant preparation, an antidandruff hair cleansing composition, a preparation for the treatment of blemished skin and acne or a preparation for the treatment of foot and/or skin fungus.Type: ApplicationFiled: February 18, 2009Publication date: December 9, 2010Applicant: AIR LIQUIDE SANTE (INTERNATIONAL)Inventors: Wolfgang Beilfuss, Klaus Weber, Ralf Gradtke, Sabine Herwig
-
Publication number: 20100310681Abstract: Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity.Type: ApplicationFiled: June 3, 2010Publication date: December 9, 2010Applicant: MARQUETTE UNIVERSITYInventor: Mohammadhossein Behnam Ghasemzadeh
-
Patent number: 7846947Abstract: The invention relates to the use of octenidine dihydrochloride for manufacturing a semisolid pharmaceutical composition for the treatment of wounds, atopic dermatitides, infected eczemas, dermatomycoses, vaginal infections, acne, herpes and/or for controlling multidrug-resistant pathogens, where the composition comprises from 0.005 to 5% by weight octenidine dihydrochloride, and a corresponding composition.Type: GrantFiled: September 12, 2006Date of Patent: December 7, 2010Assignee: Air Liquide Sante (International)Inventors: Jorg Siebert, Mona Golombiewski, Rita Blankenburg, Peter Goroncy-Bermes, Andreas Dettmann, Sabine Behrends
-
Patent number: 7842711Abstract: The invention relates to methods of treating or preventing malaria which comprises administering to a patient in need thereof, an effective amount of a 1H-indazole-3-carboxamide derivative of general formula (I), in the form of a base or of an addition salt with an acid, or in the form of a hydrate or of a solvate of said base or acid addition salt.Type: GrantFiled: September 13, 2006Date of Patent: November 30, 2010Assignee: Sanofi-AventisInventors: Hugues D'Orchymont, Laurent Fraisse, André Zimmermann
-
Publication number: 20100298284Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.Type: ApplicationFiled: April 7, 2010Publication date: November 25, 2010Inventors: Bing-Yan ZHU, Penglie ZHANG, Lingyan WANG, Wenrong HUANG, Erick A. GOLDMAN, Wenhao LI, Jingmei ZUCKETT, Yonghong SONG, Robert M. SCARBOROUGH
-
Publication number: 20100285012Abstract: The subject application provides small compounds that are able to suppress autophagy in various cells. These compounds are useful in augmenting the existing treatments of various cancers and microbial/parasitic infections. Thus, the subject application also provides methods of treating various types of cancers and microbial/parasitic infections. Also provided by the subject application are methods of suppressing the expansion of autophagosomes within cells or individuals and inhibiting the lipidation of autophagy-related protein 8 (Atg8).Type: ApplicationFiled: January 5, 2009Publication date: November 11, 2010Applicant: University of FLorida Research Foundation Inc.Inventors: William A. Dunn, JR., Debra E. Akin, Ann Progulske-Fox, David A. Ostrov
-
Patent number: 7829584Abstract: The present invention describes compounds of Formula I: wherein W, X, Y, Z, and Q are defined herein, or a pharmaceutically acceptable salt thereof, for the prophylaxis, or treatment of diseases and conditions related to thrombin activity in a mammal.Type: GrantFiled: March 13, 2007Date of Patent: November 9, 2010Assignee: Janssen Pharmaceutica NVInventors: Mark R. Player, Tianbao Lu, Huaping Hu, Xizhen Zhu, Christopher Teleha, Kevin Kreutter
-
Publication number: 20100280074Abstract: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula I in research, therapeutic, prophylactic and diagnostic methods.Type: ApplicationFiled: December 3, 2009Publication date: November 4, 2010Applicant: Millennium Pharmaceuticals, Inc.Inventors: Paul Fleming, Geraldine C.B. Harriman, Zhan Shi, Shaowu Chen
-
Publication number: 20100280075Abstract: Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C?Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and Rg are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and Rg is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ?O or ?S.Type: ApplicationFiled: January 25, 2010Publication date: November 4, 2010Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu, Mitsunori Ono
-
Publication number: 20100278933Abstract: The invention relates to kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating disorders, especially cancer.Type: ApplicationFiled: June 5, 2008Publication date: November 4, 2010Applicant: University of Florida Research Foundation, IncInventors: Peter P. Sayeski, György M. Keserü
-
Publication number: 20100273828Abstract: The present invention relates to novel 4-(4-pyridyl)-benzamides of the formula (I). The compounds I possess valuable therapeutic properties and are suitable, in particular, for treating diseases that respond to modulation of Rho kinases (ROCKs).Type: ApplicationFiled: August 26, 2008Publication date: October 28, 2010Inventors: Helmut Mack, Nicole Teusch, Bernhard K. Müller, Wilfried Hornberger, Michael F. Jarvis, Daryl Sauer, Steve Swann, JR., Anil Vasudevan
-
Publication number: 20100267697Abstract: The present teachings provide compounds of Formula (I) and pharmaceutically acceptable salts, hydrates, and esters thereof, wherein Ar, R1, R2, R3, p, and X are defined herein. The present teachings also provide processes for producing said compounds and their pharmaceutically acceptable salts, hydrates and esters, and methods of treating a pathological condition or disorder, or alleviating a symptom thereof, using said compounds including their pharmaceutically acceptable salts, hydrates and esters. The compounds can be useful in modulating ion channel activity including treating a variety of conditions associated with the abnormal modulation of one or more voltage-gated calcium channels.Type: ApplicationFiled: December 11, 2007Publication date: October 21, 2010Applicant: WyethInventors: Vincent P. Galullo, Robert Zelle, Danielle Soenen, Christopher Todd Baker, Paul Will, Hormoz Mazdiyasni, Jinsong Guo, Andrew Fensome, Jeffrey Curtis Kern, William Jay Moore, Edward George Melenski, Justin Kaplan
-
Publication number: 20100266714Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.Type: ApplicationFiled: October 29, 2008Publication date: October 21, 2010Inventors: Christopher S Burgey, Diem Nguyen, Zhengwu Deng, Daniel V. Paone, Craig M. Potteiger, Joseph P. Vacca